Radioactive dye holds promise for Alzheimer's detection

08/22/2008 | Bloomberg

U.S. scientists developed a radioactive dye called Pittsburgh Compound B that can detect Alzheimer's disease on an imaging device by binding to amyloid -- proteins linked to the condition. Backed by General Electric, the dye could help with early detection of the disease and aid drugmakers in assessing their products' efficacy in treating brain damage. Researchers are testing the dye in Alzheimer's patients with symptoms such as forgetfulness and disorientation.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance Director
Abbott Laboratories
Santa Clara, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA